GO:0098981 cholinergic synapse: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098981 cholinergic synapse is a cellular component defined as a synapse that uses acetylcholine as a neurotransmitter.
• Cholinergic synapses are essential for motor control, autonomic function, and cognitive processes such as attention and memory.
• Key molecular players include choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT), acetylcholinesterase (AChE), and nicotinic/muscarinic acetylcholine receptors.
• Dysfunction of cholinergic synapses is implicated in Alzheimer's disease, myasthenia gravis, and other neurological disorders.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of cholinergic synapse components and disease mechanisms.
• EDITGENE provides comprehensive services for generating and screening custom cell models to study cholinergic synapse biology.
Description
The cholinergic synapse (GO:0098981) is a specialized cellular component where acetylcholine (ACh) serves as the neurotransmitter. This synapse type is fundamental to the peripheral nervous system, mediating voluntary muscle contraction and autonomic functions, and is also widely distributed in the central nervous system, influencing cognition, arousal, and reward. Research into cholinergic synapses spans molecular neuroscience, pharmacology, and disease pathology, with significant implications for understanding and treating neurodegenerative and neuromuscular disorders. The precise definition and annotation of this term in the Gene Ontology (GO) database facilitate systematic studies of its components, assembly, and regulation.
cholinergic synapse At A Glance
| GO ID | GO:0098981 |
|---|---|
| GO term | cholinergic synapse |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Neurotransmission using acetylcholine |
| Key neurotransmitter | Acetylcholine (ACh) |
| Presynaptic markers | ChAT, VAChT |
| Postsynaptic receptors | Nicotinic (nAChR) and muscarinic (mAChR) acetylcholine receptors |
| Associated diseases | Alzheimer's disease, myasthenia gravis, congenital myasthenic syndromes |
What Is GO:0098981?
According to the Gene Ontology, GO:0098981 cholinergic synapse is defined as a synapse that uses acetylcholine as a neurotransmitter. This cellular component encompasses the presynaptic terminal, synaptic cleft, and postsynaptic membrane, along with the molecular machinery for ACh synthesis, storage, release, reception, and degradation.
Why Is cholinergic synapse Important in Cell Biology?
Cholinergic synapses are critical for normal physiology, controlling muscle movement, heart rate, and higher cognitive functions. Their dysfunction is a hallmark of several devastating disorders, including Alzheimer's disease, where cholinergic deficits correlate with cognitive decline, and myasthenia gravis, an autoimmune disorder targeting postsynaptic acetylcholine receptors. Understanding the molecular composition and regulation of cholinergic synapses is therefore essential for developing targeted therapies and for basic neuroscience research.
• Essential for voluntary motor control and autonomic nervous system function.
• Central to learning, memory, and attention processes.
• Primary target of Alzheimer's disease therapies (e.g., acetylcholinesterase inhibitors).
• Autoimmune attack on cholinergic synapse components causes myasthenia gravis.
• Genetic mutations in cholinergic genes lead to congenital myasthenic syndromes.
• Key model for studying synaptic plasticity and homeostatic regulation.
• Target for insecticides and chemical warfare agents (e.g., organophosphates).
• Involved in reward pathways and addiction.
• Provides insights into synaptic assembly and maintenance.
• Enables high-throughput screening for neuroactive compounds.
What Happens During cholinergic synapse?
Acetylcholine Synthesis and Storage
In simple terms: The neuron makes acetylcholine and packs it into tiny bubbles called vesicles.
In the presynaptic terminal, choline acetyltransferase (ChAT) synthesizes acetylcholine from choline and acetyl-CoA. ACh is then transported into synaptic vesicles by the vesicular acetylcholine transporter (VAChT). This storage ensures quantal release upon stimulation.
Depolarization and Neurotransmitter Release
In simple terms: When a signal arrives, the vesicles fuse with the membrane and release acetylcholine into the gap.
Action potentials trigger calcium influx, leading to SNARE-mediated fusion of ACh-containing vesicles with the presynaptic membrane. ACh is released into the synaptic cleft, where it can bind to postsynaptic receptors.
Postsynaptic Reception and Signal Transduction
In simple terms: Acetylcholine binds to receptors on the next cell, causing it to respond.
ACh binds to nicotinic (ionotropic) or muscarinic (metabotropic) acetylcholine receptors on the postsynaptic membrane. Nicotinic receptor activation causes rapid ion flux and depolarization, while muscarinic receptors trigger slower second-messenger cascades.
Termination of Signal by Acetylcholinesterase
In simple terms: An enzyme quickly breaks down acetylcholine to stop the signal.
Acetylcholinesterase (AChE) hydrolyzes ACh in the synaptic cleft into choline and acetate, terminating neurotransmission. Choline is recycled back into the presynaptic terminal for new ACh synthesis.
Key Genes Involved in GO:0098981 cholinergic synapse
The following genes encode key proteins that constitute and regulate the cholinergic synapse.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHAT | Synthesizes acetylcholine | Marker for cholinergic neurons; mutations cause congenital myasthenic syndrome |
| SLC18A3 (VAChT) | Packages ACh into vesicles | Target for studying vesicular release; knockout models show synaptic deficits |
| ACHE | Degrades acetylcholine | Inhibited in Alzheimer's therapy; mutations affect synaptic transmission |
| CHRNA1 | Nicotinic receptor subunit | Autoantibody target in myasthenia gravis |
| CHRNB1 | Nicotinic receptor subunit | Mutations cause congenital myasthenic syndromes |
| CHRND | Nicotinic receptor subunit | Associated with myasthenic syndromes |
| CHRNE | Nicotinic receptor subunit | Common mutations in congenital myasthenia |
| CHRM1 | Muscarinic receptor | Involved in cognitive functions; drug target |
| CHRM2 | Muscarinic receptor | Linked to memory and addiction |
| SLC5A7 (CHT1) | Choline transporter | Rate-limiting for ACh synthesis; knockout lethal |
| RAPSN | Clusters ACh receptors | Mutations cause congenital myasthenia |
| DOK7 | Required for AChR clustering | Mutations cause limb-girdle myasthenia |
| AGRN | Agrin, organizes postsynaptic apparatus | Essential for neuromuscular junction formation |
| LRP4 | Agrin receptor, activates MuSK | Mutations linked to myasthenia |
| MUSK | Receptor tyrosine kinase for AChR clustering | Autoantibodies in myasthenia gravis |
| COLQ | Collagen tail of AChE | Mutations cause endplate acetylcholinesterase deficiency |
| SYT1 | Synaptotagmin 1, calcium sensor for release | Regulates vesicle fusion in cholinergic synapses |
| SNAP25 | SNARE protein for vesicle fusion | Essential for neurotransmitter release |
How Is cholinergic synapse Regulated?
Cholinergic synapse function is regulated at multiple levels. Presynaptic ACh release is modulated by autoreceptors (e.g., M2 muscarinic) that inhibit further release. Postsynaptic receptor clustering is controlled by the agrin-LRP4-MuSK-DOK7 pathway. Additionally, homeostatic plasticity mechanisms adjust synaptic strength in response to activity changes.
cholinergic synapse and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHAT | Congenital myasthenic syndrome | Knockout or point-mutation cell models |
| CHRNE | Congenital myasthenia | Knock-in of patient mutations |
| ACHE | Alzheimer's disease (therapeutic target) | Overexpression or knockout for drug screening |
| MUSK | Myasthenia gravis | Autoantibody-treated cell cultures |
| RAPSN | Congenital myasthenia | Knockout and rescue with wild-type |
Alzheimer's Disease
Alzheimer's disease is characterized by progressive loss of cholinergic neurons in the basal forebrain, leading to cognitive decline. Current therapies, such as acetylcholinesterase inhibitors, aim to boost remaining cholinergic transmission.
Myasthenia Gravis
Myasthenia gravis is an autoimmune disorder where antibodies target postsynaptic acetylcholine receptors or associated proteins (e.g., MuSK, LRP4), causing muscle weakness and fatigability.
Congenital Myasthenic Syndromes
Mutations in genes such as CHAT, COLQ, RAPSN, and CHRNE lead to inherited defects in cholinergic synapse structure or function, resulting in congenital myasthenic syndromes.
From cholinergic synapse-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Role of CHAT in ACh synthesis | CHAT knockout cell line |
| Effect of AChE mutations on synaptic transmission | Point-mutation knock-in of ACHE |
| VAChT trafficking and vesicle loading | Tagged knock-in of SLC18A3 |
| Receptor clustering mechanisms | Overexpression of MUSK or RAPSN |
| Drug screening for Alzheimer's | Cholinergic neuron-like cells with AChE overexpression |
| Synaptic assembly studies | Co-culture of motor neurons and myotubes |
How to Study the cholinergic synapse Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify essential synaptic genes |
| CRISPR knock-in | Precise mutation introduction | Model congenital myasthenia mutations |
| Overexpression | Gain of function | Study receptor clustering |
| RNA-seq | Transcriptional changes | Profile cholinergic gene networks |
| Proteomics | Protein abundance and modifications | Identify synaptic protein complexes |
| Patch-clamp | Ion channel activity | Measure nicotinic receptor function |
| Fluorescence imaging | Protein localization and dynamics | Visualize synaptic vesicle cycling |
Genetic Manipulation with CRISPR
CRISPR/Cas9 allows precise knockout, point mutation, knock-in, or overexpression of cholinergic genes in cell models, enabling causal studies of synaptic components.
Imaging and Electrophysiology
Fluorescent tagging of synaptic proteins and patch-clamp recordings measure release and receptor function in real time.
Omics Approaches
Transcriptomics and proteomics identify global changes in cholinergic synapse gene expression under disease conditions.
High-Throughput Screening
CRISPR library screens can uncover novel regulators of cholinergic synapse formation and function.
How CRISPR Can Be Used to Study GO:0098981 cholinergic synapse
Knockout
CRISPR knockout of cholinergic genes (e.g., CHAT, SLC18A3) creates cell models to study loss-of-function effects on synaptic transmission and morphology.
Point Mutation
Introducing patient-specific point mutations (e.g., in CHRNE or COLQ) via CRISPR allows precise modeling of congenital myasthenic syndromes.
Knock-in
Tagged knock-in of synaptic proteins (e.g., VAChT-GFP) enables live imaging of vesicle trafficking and localization.
Overexpression
CRISPR activation or cDNA overexpression of genes like MUSK or RAPSN can drive receptor clustering and synaptic assembly in heterologous systems.
How EDITGENE Supports cholinergic synapse Research
Researchers studying cholinergic synapse-related genes often need to determine whether a candidate gene is causally involved in synaptic function or disease. EDITGENE provides tailored CRISPR services to generate precisely modified cell models, accelerating discovery in neurobiology.
Contact EDITGENE today to design your custom CRISPR model for cholinergic synapse research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ANO6 Knockout HEK293 Cell Line | EDJ-KQ228 | Human | 196527 | Details Get a Quote |
| CHRM2 Knockout HEK293 Cell Line | EDJ-KQ253 | Human | 1129 | Details Get a Quote |
| CHRM1 Knockout HEK293 Cell Line | EDJ-KQ767 | Human | 1128 | Details Get a Quote |
| CHRNA7 Knockout HEK293 Cell Line | EDJ-KQ1104 | Human | 1139 | Details Get a Quote |
| PLD1 Knockout HEK293 Cell Line | EDJ-KQ1250 | Human | 5337 | Details Get a Quote |
| BRSK1 Knockout HEK293 Cell Line | EDJ-KQ2166 | Human | 84446 | Details Get a Quote |
| CHRNA5 Knockout HEK293 Cell Line | EDJ-KQ2294 | Human | 1138 | Details Get a Quote |
| CHRNB4 Knockout HEK293 Cell Line | EDJ-KQ3485 | Human | 1143 | Details Get a Quote |
| KCNB1 Knockout HEK293 Cell Line | EDJ-KQ4237 | Human | 3745 | Details Get a Quote |
| DLGAP4 Knockout HEK293 Cell Line | EDJ-KQ7688 | Human | 22839 | Details Get a Quote |
| GPR151 Knockout HEK293 Cell Line | EDJ-KQ9339 | Human | 134391 | Details Get a Quote |
| CHRNA9 Knockout HEK293 Cell Line | EDJ-KQ12916 | Human | 55584 | Details Get a Quote |
| CHRNA10 Knockout HEK293 Cell Line | EDJ-KQ12917 | Human | 57053 | Details Get a Quote |
| DLGAP3 Knockout HEK293 Cell Line | EDJ-KQ13158 | Human | 58512 | Details Get a Quote |
| NEFL Knockout HEK293 Cell Line | EDJ-KQ13658 | Human | 4747 | Details Get a Quote |
Displaying Records 1 To 15 Of 62 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About cholinergic synapse
What is GO:0098981 cholinergic synapse?
GO:0098981 is a Gene Ontology term for a synapse that uses acetylcholine as a neurotransmitter, encompassing presynaptic and postsynaptic components.
What genes are involved in cholinergic synapse?
Key genes include CHAT, SLC18A3 (VAChT), ACHE, CHRNA1-7, CHRNB1-4, CHRM1-5, and clustering proteins like RAPSN and MUSK.
How is acetylcholine released at cholinergic synapses?
Acetylcholine is stored in vesicles and released via calcium-triggered SNARE-mediated fusion.
What diseases are associated with cholinergic synapse dysfunction?
Alzheimer's disease, myasthenia gravis, and congenital myasthenic syndromes are prominent examples.
How can CRISPR be used to study cholinergic synapses?
CRISPR enables knockout, knock-in, point mutation, and overexpression of cholinergic genes in cell models to dissect their functions.
What is the role of acetylcholinesterase in cholinergic synapses?
Acetylcholinesterase hydrolyzes acetylcholine to terminate synaptic transmission.
What are nicotinic and muscarinic receptors?
They are two classes of acetylcholine receptors: nicotinic are ionotropic, muscarinic are metabotropic.
How does myasthenia gravis affect cholinergic synapses?
Autoantibodies target postsynaptic acetylcholine receptors or associated proteins, impairing transmission.
What model systems are used to study cholinergic synapses?
Common models include knockout cell lines, patient-derived iPSCs, and co-culture systems with motor neurons and myotubes.
What services does EDITGENE offer for cholinergic synapse research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
The cholinergic synapse (GO:0098981) is a fundamental cellular component with critical roles in nervous system function and disease. Understanding its molecular architecture and regulation offers insights into neurodegenerative and neuromuscular disorders. Advanced CRISPR tools and EDITGENE's services empower researchers to create precise models for mechanistic and therapeutic studies.
References
- 1. Hampel H et al.. 2018. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.. Brain 141(7):1917-1933 PMID: 29850777
- 2. Ananth MR et al.. 2023. Basal forebrain cholinergic signalling: development, connectivity and roles in cognition.. Nat Rev Neurosci 24(4):233-251 PMID: 36823458
- 3. Prado MAM et al.. 2017. Preface: Cholinergic Mechanisms.. J Neurochem 142 Suppl 2:3-6 PMID: 28791707
- 4. Meriggioli MN et al.. 2009. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.. Lancet Neurol 8(5):475-90 PMID: 19375665
- 5. Anglister L et al.. 2021. Preface: Cholinergic mechanisms: This is the Preface for the special issue "Cholinergic Mechanisms".. J Neurochem 158(6):1212-1216 PMID: 34458988
- 6. Whittaker VP et al.. 1995. Cholinergic-specific glycoconjugates.. Neurochem Res 20(11):1377-87 PMID: 8786825
- 7. Djemil S et al.. 2023. ACh Transfers: Homeostatic Plasticity of Cholinergic Synapses.. Cell Mol Neurobiol 43(2):697-709 PMID: 35643882
- 8. Kovarik Z et al.. 2024. Recent advances in cholinergic mechanisms: A preface for the ISCM2022 special issue.. J Neurochem 168(4):334-338 PMID: 38082541
